跳转至内容
Merck
CN
  • [Inhibition of the stellate cells using lisinopril and lovastatin for prophylaxis of pancreatic stump fibrosis after performance of distal resection in a model of chronic alcoholic pancreatitis].

[Inhibition of the stellate cells using lisinopril and lovastatin for prophylaxis of pancreatic stump fibrosis after performance of distal resection in a model of chronic alcoholic pancreatitis].

Klinichna khirurhiia (2013-05-28)
M E Nichitaĭlo, D A Kravchenko, I S Shpon'ka, E B Medvetskiĭ, I M Savitskaia, I I Bulik, Iu A Khil'ko
摘要

Complex application of lisinopril (inhibitor of angiotensin-converting enzyme) and lovastatin (inhibitor of HMG-CoA reductase) inhibits pancreatic fibrosis in the rats, having alcoholic chronic pancreatitis after distal pancreatic resection (DPR). Lisinopril and lovastatin were injected to the rats after DPR in dose 10 mg/kg during 3 weeks. Immunohistochemical markets, such as alpha-smooth-muscle actin (alpha-SMA), desmin, glial fibrillary acidic protein (GFAP), vimentin, and expression of matrix metalloproteinase-1 (MMP-1) as well as inhibitor of matrix metalloproteinase-2 (TIMP-2) were detected for estimation of therapeutic impact on activity and quantity of stellate pancreatic cells. Under the influence of lisinopril and lovastatin there were observed lowering in the stellate pancreatic cells activity and in expression of SMA, desmin, GFAP, vimentin and TIMP-2, the MMP-1 and TIMP-2 ratio have had increased significantly and severity of fibrotic pancreatic affection had reduced trustworthy in comparison w such, occurring in a control group.

材料
产品编号
品牌
产品描述

Supelco
赖诺普利, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Mevinolin from Aspergillus sp., ≥98% (HPLC)
Sigma-Aldrich
赖诺普利, ≥98% (HPLC)
洛伐他汀, European Pharmacopoeia (EP) Reference Standard
洛伐他汀, European Pharmacopoeia (EP) Reference Standard